Allianz Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.18M | Buy |
6,700
+2,100
| +46% | +$1.61M | 0.01% | 1146 |
|
|
2025
Q4 | $3.55M | Hold |
4,600
| – | – | ﹤0.01% | 1308 |
|
|
2025
Q3 | $2.59M | Sell |
4,600
-800
| -15% | -$452K | ﹤0.01% | 1398 |
|
|
2025
Q2 | $2.83M | Sell |
5,400
-2,100
| -28% | -$1.17M | ﹤0.01% | 1352 |
|
|
2025
Q1 | $4.76M | Sell |
7,500
-8,700
| -54% | -$5.98M | 0.01% | 1143 |
|
|
2024
Q4 | $11.5M | Buy |
16,200
+1,400
| +9% | +$1.17M | 0.02% | 708 |
|
|
2024
Q3 | $15.6M | Buy |
14,800
+1,400
| +10% | +$1.56M | 0.02% | 602 |
|
|
2024
Q2 | $14.1M | Buy |
13,400
+1,300
| +11% | +$1.26M | 0.02% | 607 |
|
|
2024
Q1 | $11.6M | Sell |
12,100
-15,200
| -56% | -$14.5M | 0.02% | 622 |
|
|
2023
Q4 | $24M | Sell |
27,300
-4,200
| -13% | -$3.46M | 0.04% | 416 |
|
|
2023
Q3 | $25.9M | Buy |
31,500
+6,600
| +27% | +$5.19M | 0.04% | 408 |
|
|
2023
Q2 | $17.9M | Buy |
24,900
+9,300
| +60% | +$7.17M | 0.03% | 493 |
|
|
2023
Q1 | $12.8M | Buy |
15,600
+12,100
| +346% | +$9.13M | 0.02% | 610 |
|
|
2022
Q4 | $2.53M | Buy |
3,500
+3,300
| +1,650% | +$2.43M | ﹤0.01% | 1210 |
|
|
2022
Q3 | $138K | Sell |
200
-1,300
| -87% | -$818K | ﹤0.01% | 1657 |
|
|
2022
Q2 | $887K | Sell |
1,500
-1,200
| -44% | -$780K | ﹤0.01% | 1713 |
|
|
2022
Q1 | $1.89M | Sell |
2,700
-500
| -16% | -$316K | ﹤0.01% | 1615 |
|
|
2021
Q4 | $2.02M | Sell |
3,200
-900
| -22% | -$553K | ﹤0.01% | 1603 |
|
|
2021
Q3 | $2.48M | Buy |
4,100
+2,100
| +105% | +$1.3M | ﹤0.01% | 1578 |
|
|
2021
Q2 | $1.12M | Buy |
2,000
+600
| +43% | +$304K | ﹤0.01% | 1695 |
|
|
2021
Q1 | $662K | Buy |
+1,400
| New | +$682K | ﹤0.01% | 1789 |
|
|
2020
Q3 | – | Sell |
-19,000
| Closed | -$11.8M | – | 2306 |
|
|
2020
Q2 | $11.8M | Buy |
19,000
+14,200
| +296% | +$8.06M | 0.01% | 822 |
|
|
2020
Q1 | $2.34M | Sell |
4,800
-8,300
| -63% | -$3.42M | ﹤0.01% | 1472 |
|
|
2019
Q4 | $4.92M | Buy |
13,100
+2,400
| +22% | +$807K | ﹤0.01% | 1488 |
|
|
2019
Q3 | $2.97M | Buy |
10,700
+4,400
| +70% | +$1.3M | ﹤0.01% | 1667 |
|
|
2019
Q2 | $1.97M | Buy |
6,300
+1,200
| +24% | +$400K | ﹤0.01% | 1892 |
|
|
2019
Q1 | $2.09M | Sell |
5,100
-37,900
| -88% | -$15.6M | ﹤0.01% | 1828 |
|
|
2018
Q4 | $16.1M | Sell |
43,000
-8,600
| -17% | -$3.15M | 0.02% | 821 |
|
|
2018
Q3 | $20.8M | Sell |
51,600
-8,200
| -14% | -$3.12M | 0.02% | 874 |
|
|
2018
Q2 | $20.6M | Buy |
59,800
+3,300
| +6% | +$1.03M | 0.02% | 872 |
|
|
2018
Q1 | $19.5M | Sell |
56,500
-165,900
| -75% | -$57.7M | 0.02% | 897 |
|
|
2017
Q4 | $83.6M | Buy |
222,400
+15,300
| +7% | +$6.2M | 0.07% | 355 |
|
|
2017
Q3 | $92.6M | Buy |
207,100
+52,500
| +34% | +$25M | 0.08% | 293 |
|
|
2017
Q2 | $75.9M | Buy |
154,600
+11,600
| +8% | +$5.08M | 0.07% | 320 |
|
|
2017
Q1 | $55.4M | Sell |
143,000
-62,300
| -30% | -$23.1M | 0.05% | 435 |
|
|
2016
Q4 | $75.4M | Buy |
205,300
+108,300
| +112% | +$41.2M | 0.07% | 364 |
|
|
2016
Q3 | $39M | Buy |
97,000
+300
| +0.3% | +$120K | 0.04% | 590 |
|
|
2016
Q2 | $33.8M | Buy |
96,700
+62,300
| +181% | +$24M | 0.04% | 612 |
|
|
2016
Q1 | $12.4M | Buy |
34,400
+2,200
| +7% | +$907K | 0.01% | 1024 |
|
|
2015
Q4 | $17.5M | Buy |
32,200
+13,100
| +69% | +$7.1M | 0.02% | 811 |
|
|
2015
Q3 | $8.88M | Buy |
19,100
+6,200
| +48% | +$3.33M | 0.01% | 1037 |
|
|
2015
Q2 | $6.58M | Buy |
12,900
+2,500
| +24% | +$1.22M | 0.01% | 1283 |
|
|
2015
Q1 | $4.7M | Buy |
10,400
+800
| +8% | +$339K | 0.01% | 1234 |
|
|
2014
Q4 | $3.94M | Buy |
9,600
+7,800
| +433% | +$3.07M | ﹤0.01% | 1301 |
|
|
2014
Q3 | $649K | Buy |
+1,800
| New | +$603K | ﹤0.01% | 1810 |
|
Other funds holding REGN
VCM
N
Allianz Asset Management's REGN Position: Q1 2026 in Review
Allianz Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 79% in Q1 2026, buying an estimated $102M and bringing the position to 301,196 shares worth $233M. The position accounts for 0.24% of the portfolio, ranked #77.
Allianz Asset Management first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Allianz Asset Management held 301,196 shares of Regeneron Pharmaceuticals worth $233M as of Q1 2026.
- Allianz Asset Management bought 132,582 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $102M.
- Regeneron Pharmaceuticals made up 0.24% of Allianz Asset Management's portfolio in Q1 2026, its #77 holding.
- Allianz Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.